The Schistosomiasis Vaccine Initiative was launched in 2008 through funding from Mr. Morton Hyman and the Blavatnik Family Foundation. In collaboration with researchers at James Cook University and The George Washington University, a promising antigen, Sm-TSP-2, was selected for development.
Development of the manufacturing process for Sm-TSP-2 schistosomiasis vaccine begins.
Sabin Vaccine Institute acquires the exclusive license to the intellectual property for Sm-TSP-2 antigen from the Queensland Institute of Medical Research. Patent applications are filed in the United States, Brazil, Australia and India.
Sabin Vaccine Development receives its initial funding from private donors to establish SVI and develop the Sm-TSP-2 schistosomiasis vaccine.